Emerging therapies in idiopathic inflammatory myopathies

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Idiopathic inflammatory myopathies (IIM), or myositis, are rare autoimmune disorders causing muscle and extramuscular inflammation.
• Current treatments for IIM lack robust evidence, with many patients experiencing persistent disease activity and reduced quality of life despite therapy.
• Challenges in IIM management include disease heterogeneity, rare occurrence, systemic involvement, and limited understanding of pathogenesis.

Purpose of the Study:

• To review the immunopathogenesis of IIM, including the roles of autoantibodies, B cells, T cells, interferon pathways, and complement.
• To discuss current therapeutic strategies for IIM.
• To provide an overview of emerging and promising novel treatments for IIM.

Main Methods:

• Review of existing literature on IIM immunopathogenesis and treatment.
• Analysis of recent and ongoing clinical trials for novel IIM therapies.
• Discussion of molecular and cellular mechanisms underlying IIM.

Main Results:

• Recent insights have identified novel therapeutic targets in IIM.
• Emerging treatments include CAR T-cell therapy, T-cell engagers, FcRn inhibitors, and small-molecule inhibitors (JAKs, IFN, complement).
• Understanding IIM pathogenesis is crucial for developing effective therapies.

Conclusions:

• Despite challenges, advances in understanding IIM pathogenesis are paving the way for targeted therapies.
• Novel treatments show promise for improving outcomes in patients with idiopathic inflammatory myopathies.
• Further research and clinical trials are essential to validate new therapeutic approaches for IIM.